Navigation Links
Long Term Data Presented at EuroPCR 2009 from Randomized Study Attest to Durability of Results of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) Compared to Drug-Eluting Stents
Date:5/20/2009

Other Presentations Highlight Pre-clinical Work of Company's Future Pro-healing Technologies

BARCELONA, Spain, May 20 /PRNewswire/ -- OrbusNeich announced today that two year follow up data from a single center, randomized clinical study in patients at high risk of restenosis were presented at EuroPCR 2009, demonstrating stable results in patients treated with the company's Genous Bio-engineered R stent, the world's first pro-healing stent, compared with results from patients treated with a drug-eluting stent.

Presented by Marcel Beijk, M.D., of the Academic Medical Center in Amsterdam, two year follow up data from the single center TRIAS HR (high risk) study show similar mortality (5.1% vs 4.2%) and target lesion revascularization (TLR) rates (15.3% vs 13.7%) for the Genous Bio-engineered R stent compared to Boston Scientific's Taxus(R) Liberte stent in high risk of restenosis patients. However, the thrombosis rate for Taxus treated patients increased from one to two years from 4.2% to 5.3%, with another event occurring at 658 days in a patient who had previously presented with a subacute thrombosis and who was on dual antiplatelet therapy at the time of both thromboses. There were no thrombotic events in the Genous treated group at any time period (0.0%). Myocardial infarctions (MI) increased from years one to two in the Taxus patients to 6.3%, while the MI rate in the Genous patients remained steady at 3.1%, all of which were peri-procedural.

"While both groups of patients showed good clinical outcomes, the Genous treated patients were relatively stable between one and two years," said Beijk.

TRIAS HR is a randomized, 193-patient, single-center, prospective study involving patients with a high risk of restenosis. High risk of restenosis is defined as patients who have diabetes mellitus and/or small vessels (less than or equal to 2.8 mm) and/or long lesions (greater than or equal to 23 mm) and/or chronic total occlusions. Two year follow up was obtained in all patients, with the exception of one.

The next generation of pro-healing stent technologies was highlighted in separate presentations, one focusing on pre-clinical results of an endothelial cell capture (EPC) surface on an abluminal, low dose sirolimus eluting stent (pro-healing SES), the other focusing on the company's bioabsorbable stent developments.

Greg Kaluza, M.D., Ph.D., Director of Operations at the Jack H. Skirball Center for Cardiovascular Research in New York, presented the pro-healing SES's pre-clinical results from multiple models supporting the soon to be initiated first in human study. The pro-healing SES demonstrated significantly lower neointimal hyperplasia, while also showing improved endothelial coverage relative to two other commercially available DES. There was also a noticeably lower presence of inflammation and foreign body reaction. "These data are remarkably promising across all criterion," said Kaluza. "For the first time, a DES appears effective at inhibition of neointima while enhancing endothelial coverage early on."

Development of the company's bioabsorbable stent program was presented by Robert Cottone, vice president of intellectual property and technologies. Angiographic and optical coherence tomography (OCT) imagery were reviewed illustrating the new stent platform's deliverability, design features, and vessel scaffolding. "The nature of the polymeric materials allows for tremendous innovation in stent design and functionality," said Cottone. "With this new platform, combined with our coating technologies, we will be able to achieve clinical vascular restoration therapies simply not possible with metal."

Unlike drug-eluting stents, Genous, which is coated with an antibody, captures a patient's EPCs to accelerate the natural healing process. EPCs circulate in the bloodstream and are involved in the repair of blood vessels. When attracted to the surface of Genous, EPCs rapidly form an endothelial layer over the stent, providing a safe and effective alternative to DES.

OrbusNeich designs, develops, manufactures and markets innovative medical devices for the treatment of vascular diseases. Other products in the company's product portfolio are stents, balloons and guiding catheters marketed under the names of Blazer(TM), R stent, Scoreflex(TM), SafeCut(TM), Sapphire(TM), Sapphire NC, Avita(TM), Avita HP, and Lumina(TM).

A global company, OrbusNeich is headquartered in Hong Kong and has operations in Fort Lauderdale, FL; Hoevelaken, The Netherlands; Tokyo, Japan; and Shenzhen, China. OrbusNeich, which has provided cardiology devices to physicians through its predecessor companies since 1979, today supplies products to interventional cardiologists in more than 60 countries. For more information, visit www.orbusneich.com.

Editor's Note: OrbusNeich is displaying the Genous Bio-engineered R stent at Booth No. F06 at EuroPCR 2009.


'/>"/>
SOURCE OrbusNeich
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS)
2. Clinical Data on Semafores SF1126, a Vascular Targeted Pan-PI3K/mTOR Inhibitor, to be Presented at the 2009 ASCO Meeting
3. Pixantrone Phase 3 Data to be Presented at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting
4. Autism Studies Presented at Mid-Atlantic Research Consortium Meeting
5. Two-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients With Multiple Sclerosis
6. New Studies on Once-Daily Extended Release Pramipexole Presented at American Academy of Neurology Annual Meeting
7. Data Presented at AUA Demonstrate PROVENGE Significantly Prolongs Survival for Men With Advanced Prostate Cancer in Pivotal Phase 3 IMPACT Study
8. Data Presented at AACR Annual Meeting Show Anti-Tumor Activity of Peregrines Fully Human Anti-PS Antibody in Prostate Cancer Model
9. Processed Tomato Products May Protect Against Inflammation, According to a Study Presented at the Experimental Biology Meeting
10. Studies Presented at AACR Annual Meeting Highlight Multiple Immunomodulatory Mechanisms of Peregrines PS-Targeting Antibodies
11. Cequent tkRNAi Technology to be Presented at the Centennial Meeting of the American Association for Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 24, 2016   Bay Area Lyme Foundation ... Dean Center for Tick Borne Illness , Harvard ... MIT Hacking Medicine, University of California, Berkeley, and ... the five finalists of Lyme Innovation , ... than 100 scientists, clinicians, researchers, entrepreneurs, and investors ...
(Date:6/24/2016)... 24, 2016 Research and ... "Structural Electronics 2015-2025: Applications, Technologies, Forecasts" report ... In-Mold Electronics, Smart Skin, Structural Health Monitoring, ... Structural electronics involves electronic and/or electrical components ... replacing dumb structures such as vehicle bodies or ...
(Date:6/24/2016)... Dehaier Medical Systems Ltd. (NASDAQ: DHRM ) ... medical devices and wearable sleep respiratory products in ... with Hongyuan Supply Chain Management Co., Ltd. (hereinafter referred ... to develop Dehaier,s new Internet medical technology business. ... Hongyuan Supply Chain,s sales platform to reach Dehaier,s dealers ...
Breaking Medicine Technology:
(Date:6/27/2016)... , ... June 27, 2016 , ... TopConsumerReviews.com recently awarded ... Eyeglasses . , Millions of individuals in the United States and Canada wear ... a way to both correct vision and make a fashion statement. Even celebrities use ...
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ProSlice Levels, a Media ... give their videos a whole new perspective by using the title layers in ... Studios. , ProSlice Levels contains over 30 Different presets to choose from. ...
(Date:6/26/2016)... Birmingham, Lake Orion, Clarkston, Michigan (PRWEB) , ... ... ... their direction with respect to fertility once they have been diagnosed with endometriosis. ... for tolerable intercourse but they also require a comprehensive approach that can help ...
(Date:6/25/2016)... ... ... closing of Bruton Memorial Library on June 21 due to a possible lice infestation, as ... of head lice: the parasite’s ability to live away from a human host, and to ... one in the event that lice have simply gotten out of control. , As lice ...
(Date:6/25/2016)... ... ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his Bachelors in ... School of Medicine at UCLA. He trained in Internal Medicine at Scripps Green Hospital ... at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to train in ...
Breaking Medicine News(10 mins):